all ( 24 results found)
DHPC - Risk of secondary malignancy of T-cell origin in CD19- or BCMA-directed CAR T-cell therapies
DHPC communication - restriction of use in neonates as concentration of the excipient, propylene glycol, exceeds recommended threshold
DHPC enzalutamide test interference leading to falsely elevated digoxin plasma levels
Direct healthcare professional communication (DHPC) - Evrysdi 0.75 mg/mL powder for oral solution (risdiplam)
Dzuveo cover letter
Dzuveo DHCP letter
EpiPen® Healthcare Professional Letter
EpiPen® Healthcare Professional Letter
Finasteride, dutasteride – New measures to minimise the risk of suicidal ideation
Fluoroquinolones DHPC_HPRA_FINAL vs2 30-05-23
IE Adcortyl Discontinuation Letter June 2025
Infanrix Hexa - DHPC
Product Recall Palmeux - pharmacy letter
Product Recall Palmeux - pharmacy letter
Product Recall Palmeux - pharmacy letter
Product Recall Palmeux- pharmacy letter
Risperidone 1mg per ml OS-Risk of medication errors leading to accidental overdoses in children and adolescents
Topiramate: New restrictions to prevent exposure during pregnancy
Topiramate: New restrictions to prevent exposure during pregnancy
Topiramate: New restrictions to prevent exposure during pregnancy
Topiramate: New restrictions to prevent exposure during pregnancy
Topiramate: New restrictions to prevent exposure during pregnancy
Topiramate: New restrictions to prevent exposure during pregnancy
Veoza - 45mg film-coated tablets_DHPC January 2025
Zadenvi HCP Letter